Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the ...

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance's full-year ...

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved success. Could it even be a millionaire-maker? To appreciate Iovance's ...

Iovance Biotherapeutics shares fell 6.41% after appointing Dan Kirby as Chief Commercial Officer, signaling investor concerns. The decline reflects skepticism about the company's growth trajectory ...

Newly commercial stage biopharma Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has delivered a couple of quarterly earnings beats since we last put in the spotlight in July of this year. The company ...

While that level of success is only obvious in hindsight, Iovance Biotherapeutics (NASDAQ: IOVA) is an emerging industry leader with significant potential. The company's tumor-infiltrating ...

Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials ...